BR112023024853A2 - Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer - Google Patents
Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncerInfo
- Publication number
- BR112023024853A2 BR112023024853A2 BR112023024853A BR112023024853A BR112023024853A2 BR 112023024853 A2 BR112023024853 A2 BR 112023024853A2 BR 112023024853 A BR112023024853 A BR 112023024853A BR 112023024853 A BR112023024853 A BR 112023024853A BR 112023024853 A2 BR112023024853 A2 BR 112023024853A2
- Authority
- BR
- Brazil
- Prior art keywords
- abt
- free base
- phenylethylamino
- enamide
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218504P | 2021-07-06 | 2021-07-06 | |
| PCT/US2022/036260 WO2023283269A1 (en) | 2021-07-06 | 2022-07-06 | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024853A2 true BR112023024853A2 (pt) | 2024-02-15 |
Family
ID=84802010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024853A BR112023024853A2 (pt) | 2021-07-06 | 2022-07-06 | Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12240858B2 (enExample) |
| EP (1) | EP4330259A4 (enExample) |
| JP (1) | JP7565118B2 (enExample) |
| KR (1) | KR102783648B1 (enExample) |
| CN (1) | CN116916922B (enExample) |
| AU (1) | AU2022307875B2 (enExample) |
| BR (1) | BR112023024853A2 (enExample) |
| CA (1) | CA3217088A1 (enExample) |
| IL (1) | IL308946B2 (enExample) |
| MX (1) | MX2023013093A (enExample) |
| TW (1) | TWI809967B (enExample) |
| WO (1) | WO2023283269A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI906763B (zh) * | 2024-02-05 | 2025-12-01 | 財團法人國家衛生研究院 | 表皮生長因子受體抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507502B2 (en) * | 2008-11-10 | 2013-08-13 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| KR101301533B1 (ko) * | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
-
2022
- 2022-07-05 TW TW111125153A patent/TWI809967B/zh active
- 2022-07-06 JP JP2023544357A patent/JP7565118B2/ja active Active
- 2022-07-06 CA CA3217088A patent/CA3217088A1/en active Pending
- 2022-07-06 BR BR112023024853A patent/BR112023024853A2/pt unknown
- 2022-07-06 CN CN202280009812.5A patent/CN116916922B/zh active Active
- 2022-07-06 IL IL308946A patent/IL308946B2/en unknown
- 2022-07-06 WO PCT/US2022/036260 patent/WO2023283269A1/en not_active Ceased
- 2022-07-06 AU AU2022307875A patent/AU2022307875B2/en active Active
- 2022-07-06 KR KR1020237023847A patent/KR102783648B1/ko active Active
- 2022-07-06 MX MX2023013093A patent/MX2023013093A/es unknown
- 2022-07-06 US US17/858,321 patent/US12240858B2/en active Active
- 2022-07-06 EP EP22838355.0A patent/EP4330259A4/en active Pending
-
2024
- 2024-07-17 US US18/775,916 patent/US20240368175A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202309041A (zh) | 2023-03-01 |
| JP2024514995A (ja) | 2024-04-04 |
| US12240858B2 (en) | 2025-03-04 |
| IL308946A (en) | 2024-01-01 |
| KR102783648B1 (ko) | 2025-03-18 |
| IL308946B2 (en) | 2026-01-01 |
| CA3217088A1 (en) | 2023-01-12 |
| CN116916922A (zh) | 2023-10-20 |
| TWI809967B (zh) | 2023-07-21 |
| WO2023283269A1 (en) | 2023-01-12 |
| AU2022307875A1 (en) | 2023-11-02 |
| CN116916922B (zh) | 2026-01-02 |
| AU2022307875B2 (en) | 2024-08-01 |
| US20230021909A1 (en) | 2023-01-26 |
| EP4330259A4 (en) | 2024-10-09 |
| KR20230118963A (ko) | 2023-08-14 |
| EP4330259A1 (en) | 2024-03-06 |
| JP7565118B2 (ja) | 2024-10-10 |
| IL308946B1 (en) | 2025-09-01 |
| US20240368175A1 (en) | 2024-11-07 |
| MX2023013093A (es) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010879A2 (pt) | inibidores da proteína quinase, método de preparação e uso médico dos mesmos | |
| BRPI0519774A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| BRPI0514288A (pt) | benzamidas substituìdas com triflúor-metila como inibidores de cinases | |
| TW200811130A (en) | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| MX2023006854A (es) | Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma. | |
| BR112022009705A2 (pt) | Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| RU2015117647A (ru) | Новые производные пиразола | |
| WO2013178581A1 (en) | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| JPWO2020095971A5 (enExample) | ||
| BR112023025841A2 (pt) | Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| JPWO2020175629A5 (enExample) | ||
| BR112023024853A2 (pt) | Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer | |
| BR112022000523A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| AU2008203743B2 (en) | Thioxanthene derivates useful to treat infectious diseases | |
| IL274233B1 (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| JP2021510168A5 (enExample) |